Considering the high percentages of HER-2 positive subtypes in the young cohort, further studies focusing on potential mechanisms of liver and bone metastases in HER-2 positive breast cancer may help in developing novel strategies for metastasis prevention. This evidence concerns the gene ERBB2 and breast cancer.